Therapies that inhibit HIF1α directly or modulate its associated regulatory mechanisms, such as the SMURF2 pathway, have the potential to impair tumor angiogenesis, reduce immune suppression, and reprogram tumor metabolism. This evidence concerns the gene SMURF2 and neoplasm.